Navigation Links
InfoGroup Founder and Board Member Criticizes Adoption of Poison Pill
Date:5/18/2009

Board Should Pursue Strategic Alternatives Rather than Seek to Entrench Itself

OMAHA, Neb., May 18 /PRNewswire/ -- Vinod Gupta, the founder, member of the board of directors and holder of approximately 39% of the outstanding stock of InfoGroup (Nasdaq: IUSA) announced today that he strongly disagreed with the Company's recent decision to adopt a poison pill and believes that the Company must explore strategic alternatives.

"I believe that the Board of Directors' adoption of a 'poison pill' demonstrates that many of the directors are willing to entrench themselves at the expense of the Company's stockholders," said Mr. Gupta. "Unfortunately, this conduct is consistent with past Board actions. When I entered into a settlement agreement with the Company in 2008, the Board insisted that I vote all my shares in favor of the Board's nominees for director rather than proportionately with the shares of the Company's unaffiliated stockholders, as I had strongly demanded. The Board simply wanted to control my votes (approximately 39% of the Company's voting stock) to assure that they could keep their board seats rather than give the stockholders, to whom they should owe their allegiance, a meaningful say in the election of directors," Mr. Gupta stated.

"I regret that some members of this Board, who do not own a meaningful amount of stock in the Company like I do, seem much more interested in assuring that they retain their directorships than in doing what is best for the stockholders of the Company. I sincerely hope that all stockholders, as well as Risk Metrics, let these members of the Board know their displeasure with the Board's decision to adopt a rights plan," Mr. Gupta continued.

"It is bad enough that a majority of the Board would take this action against the best interests of all of the stockholders. However, in my case, their conduct amounts to a breach by the Board of an agreement between the Company and me, as described in the letter to the Board attached to this press release," said Mr. Gupta.

"Even the adoption of the poison pill might not be so bad in isolation. But the poison pill has to be judged against the background of the Company's dismal performance since new management was installed and other actions by a majority of the Board to feather the nest of directors and senior management. These include:

  • The Company's revenues in the March 2009 quarter declined 17% and operating income declined 34% from the first quarter of last year.
  • These results are much worse than the Company's peer group: in the March 2009 quarter, Dun & Bradstreet's revenues only declined 2% and its operating income actually increased 5% from the first quarter of last year.
  • The Board has discontinued the Company's annual dividend, depriving the stockholders of last year's dividend of $0.35 per share.
  • This dismal performance hasn't stopped the Board from treating itself and management quite well.
    • Four of the directors received directors fees of approximately $296,000, $288,000, $273,000 and $248,000, respectively, in 2008. This is a total of directors fees of approximately $1,105,000 for just these four directors.
    • The Board gave away more than 900,000 shares of restricted stock to senior management.
    • The Board gave change of control benefits for the four top officers that could total approximately $9,400,000.
    • The Board provided a compensation package to its new CEO, who has no experience in the industry, which contemplates $1,500,000 annual cash compensation as well as discretionary equity compensation. In 2008, the fair value of the CEO's discretionary equity compensation was $726,000, such that his total 2008 compensation was $2,226,000.

Mr. Gupta said.

"I strongly believe that it is in the best interests of the stockholders for the Board to explore the Company's strategic alternatives rather than for the Board to seek to entrench itself and waste money on the Board and the Company's top executives. In my capacity as a stockholder of the Company, I have been approached by both strategic and financial buyers about potential transactions but I believe the Company has failed to engage with them in any meaningful way. I remain open to a sale of the Company and would be willing to participate (or not participate) with the buyer if that helped get a transaction done," Mr. Gupta concluded.


'/>"/>
SOURCE Vinod Gupta
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
2. Center for Health Transformation Founder Newt Gingrich Calls on Congress to Pass a Clean SCHIP Six-Month Extension
3. Forbes Honors Susan G. Komen for the Cure Founder as Trailblazer
4. Cardinal Health Names CEO R. Kerry Clark as Chairman; Company Founder Robert D. Walter to Retire After 36 Years
5. Susan G. Komen for the Cure Founder Sworn in as Chief of Protocol
6. FalconStor Software Inc. Founders Make Multi-Million Dollar Donation to North Shore-LIJ Health System for Asian Community Health Center in Flushing
7. GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
8. Former NFL Star Tiki Barber and CURE Founder Susan Axelrod Speak Out About Epilepsy on TODAY Show
9. Lenny Dykstra, Founder & President of The Players Club, to Keynote the 2008 Financial Communications Forum
10. Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation
11. Childrens Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2016)... ... February 14, 2016 , ... Many eating ... professionals near their residence. The nature of the illnesses requires ongoing supervision, therapy ... time allotted at work to make traditional appointments. These people struggle to maintain ...
(Date:2/13/2016)... ... February 13, 2016 , ... Good news for retinal patients ... area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, imaging technology used to ... diabetic retinopathy, and other vascular conditions. , In just a few seconds, OCT ...
(Date:2/13/2016)... Angeles, California (PRWEB) , ... February 13, 2016 , ... ... help landing a date for the big day. A great outfit, flawless hair, and ... ashtray, they might as well resign themselves to a night at home with Rover. ...
(Date:2/13/2016)... ... ... individuals looking to lead a healthy lifestyle have decreased carbohydrate consumption and increased their ... delved into this niche allowing those giving up their beloved pasta a chance to ... of protein and only 7 grams of carbohydrates per 50 gram serving--a ratio that ...
(Date:2/13/2016)... FL (PRWEB) , ... February 13, 2016 , ... The ... environmental impact of American businesses. , The increasingly modern world of instantaneous consumption ... often on non-renewable energy sources such as oil and coal, which pollutes our air, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ) ... will ring the Nasdaq Closing Bell at the Nasdaq ... at 4:00 p.m. ET on Tuesday, February 16, ... Adrian Adams , will perform the honorary bell ... p.m. ET.  A live webcast will be available at: ...
(Date:2/12/2016)... , Maharashtra, February 12, 2016 ... research report titled Chronic Inflammation Global Clinical Trials ... snapshot of the global clinical trials landscape along ... trials by Region, Country (G7 & E7), Trial ... status and reviews top companies involved and enlists ...
(Date:2/11/2016)... Laboratory glassware and plasticware include ... may range from microscope slides to large storage boxes ... borosilicate glass because of its low weight and resistance ... started gaining popularity over the past decade when it ... with plastic in several applications due to its resistance ...
Breaking Medicine Technology: